Hpgc Renmintongtai Pharmaceutical Corporation’s Net Profit Rose 56.5% in First Quarter of 2023

Hpgc Renmintongtai Pharmaceutical Corporation (哈药集团人民同泰医药股份有限公司) (600829.SH) reported a net profit of 72.1 million yuan in the first quarter of 2023, up 56.5% year-on-year.

Meanwhile, the company posted 2.7 billion yuan in revenue, up 13.9% year-on-year.

At the end of the reporting period, it had 7.1 billion yuan in total assets and 4.6 billion yuan in total liabilities, with a liability-to-asset ratio of 64.5%.